MicroRNA 3606 (MIR3606)

MicroRNA 3606 (MIR3606) is a human gene encoding a microRNA, part of a large family of short non-coding RNAs (miRNAs)[2][4]. MicroRNAs act as post-transcriptional regulators of gene expression, primarily binding to complementary sequences in the 3'-untranslated regions (UTRs) of target messenger RNAs (mRNAs)[2][3][4]. This generally leads to mRNA destabilization and/or translational inhibition via the RNA-induced silencing complex (RISC) pathway[2][3][4]. The canonical human miRNA biogenesis pathway involves transcription by RNA polymerase II, nuclear processing by Drosha/DGCR8, cytoplasmic export via Exportin-5, and maturation by Dicer, before the "guide strand" loads into an Argonaute protein[2][3][4].\n\nDespite this general functional paradigm for miRNAs, there is currently no published functional, mechanistic, or disease data for MIR3606 itself. MIR3606 is included in comprehensive miRNA expression studies and databases, suggesting it is expressed in human tissues but without reported specificity or direct biologic impact[1][2]. There is no evidence that MIR3606 is commonly used as a therapeutic target, clinical biomarker, or has interacting drugs. It is not recognized as a receptor, enzyme, or other classic drug target class. The sequence and processing features of MIR3606 would fit the standard criteria for a canonical microRNA, but without experimentally validated functions or disease associations, this locus is best considered a "putative microRNA gene"[2]. There are no established safety concerns, disease roles, or mechanisms of drug action specific to MIR3606[2][3][4].\n\nIn summary, MIR3606 is a poorly characterized human microRNA gene with no known function, disease link, or utility as a drug target or biomarker[2][3][4].

Other names

MIR3606hsa-mir-3606mir-3606